Granite Point Capital Management, L.P. Tcr2 Therapeutics Inc. Transaction History

Granite Point Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$8.44 - $18.35 $202,560 - $440,400	-24,000 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$20.38 - $34.07 $529,880 - $885,820	-26,000 Reduced 52.0%	24,000 $530,000
Q3 2020 Nov 06, 2020	SELL	$13.1 - $20.69 $655,000 - $1.03 Million	-50,000 Reduced 50.0%	50,000 $1.02 Million
Q2 2020 Aug 12, 2020	BUY	$6.51 - $16.85 $651,000 - $1.69 Million	100,000 New	100,000 $1.54 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.